Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Jane Street Group LLC

Key Points

• Jane Street Group LLC significantly increased its stake in Bio-Rad Laboratories, raising its position by 95.3% to own 37,383 shares worth approximately $9.1 million as of the latest SEC filing.
• Several other institutional investors also boosted their holdings in Bio-Rad, with Bank of America increasing its stake by 705.9% and GAMMA Investing LLC by 22,131.7% in the first quarter.
• Analysts have mixed ratings on Bio-Rad, with Wells Fargo raising its target price to $265.00 while Royal Bank of Canada set a higher target of $409.00, reflecting a current consensus rating of "Moderate Buy."

Jane Street Group LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 95.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,383 shares of the medical research company's stock after buying an additional 18,239 shares during the period. Jane Street Group LLC owned about 0.13% of Bio-Rad Laboratories worth $9,105,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Curat Global LLC bought a new position in Bio-Rad Laboratories during the 1st quarter worth approximately $34,000. Allworth Financial LP lifted its holdings in Bio-Rad Laboratories by 260.0% during the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock worth $36,000 after buying an additional 104 shares during the last quarter. Headlands Technologies LLC lifted its holdings in Bio-Rad Laboratories by 64.1% during the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock worth $87,000 after buying an additional 139 shares during the last quarter. Skylands Capital LLC bought a new position in Bio-Rad Laboratories during the 1st quarter worth approximately $122,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Bio-Rad Laboratories during the 1st quarter worth approximately $206,000. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO traded up $5.84 during mid-day trading on Friday, hitting $295.27. The company had a trading volume of 257,890 shares, compared to its average volume of 211,765. The stock has a market cap of $7.99 billion, a price-to-earnings ratio of 25.17 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The firm's 50 day simple moving average is $268.80 and its two-hundred day simple moving average is $251.78.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.68. The business had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The business's revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $3.11 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on BIO shares. Royal Bank Of Canada increased their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Wells Fargo & Company increased their target price on Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, August 22nd. Finally, Zacks Research raised Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $333.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.